KalVista Pharmaceuticals Inc (NASDAQ: KALV) started the day on Wednesday, with a price decrease of -3.44% at $12.07, before settling in for the price of $12.50 at the close. Taking a more long-term approach, KALV posted a 52-week range of $7.30-$15.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -24.26%. Meanwhile, its Annual Earning per share during the time was -20.06%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -3.28%. This publicly-traded company’s shares outstanding now amounts to $49.49 million, simultaneously with a float of $38.56 million. The organization now has a market capitalization sitting at $600.07 million. At the time of writing, stock’s 50-day Moving Average stood at $10.35, while the 200-day Moving Average is $11.11.
KalVista Pharmaceuticals Inc (KALV) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. KalVista Pharmaceuticals Inc’s current insider ownership accounts for 22.44%, in contrast to 89.02% institutional ownership. According to the most recent insider trade that took place on Mar 07 ’25, this organization’s CHIEF EXECUTIVE OFFICER sold 6,669 shares at the rate of 11.97, making the entire transaction reach 79,828 in total value, affecting insider ownership by 287,811. Preceding that transaction, on Feb 24 ’25, Company’s CHIEF MEDICAL OFFICER sold 2,394 for 10.02, making the whole transaction’s value amount to 23,988. This particular insider is now the holder of 102,940 in total.
KalVista Pharmaceuticals Inc (KALV) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.95 per share during the current fiscal year.
KalVista Pharmaceuticals Inc’s EPS decrease for this current 12-month fiscal period is -3.28% and is forecasted to reach -2.97 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 20.85% through the next 5 years, which can be compared against the -20.06% growth it accomplished over the previous five years trading on the market.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Trading Performance Indicators
Let’s observe the current performance indicators for KalVista Pharmaceuticals Inc (KALV). It’s Quick Ratio in the last reported quarter now stands at 10.44. The Stock has managed to achieve an average true range (ATR) of 0.62.
In the same vein, KALV’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.73, a figure that is expected to reach -0.85 in the next quarter, and analysts are predicting that it will be -2.97 at the market close of one year from today.
Technical Analysis of KalVista Pharmaceuticals Inc (KALV)
If we take a close look at the recent performances of KalVista Pharmaceuticals Inc (NASDAQ: KALV), its last 5-days Average volume was 0.72 million that shows progress from its year to date volume of 0.46 million. During the previous 9 days, stock’s Stochastic %D was recorded 54.84% While, its Average True Range was 0.61.
Raw Stochastic average of KalVista Pharmaceuticals Inc (KALV) in the period of the previous 100 days is set at 85.18%, which indicates a major rise in contrast to 39.42% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 32.16% that was lower than 57.17% volatility it exhibited in the past 100-days period.
